Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
312 GBX | +4.00% | +7.59% | +10.25% |
26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.25% | 3.2B | |
+33.25% | 699B | |
+24.98% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+15.09% | 236B | |
+4.91% | 198B | |
-10.43% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Hutchmed, AstraZeneca Launch Late-Stage Study of Kidney Cancer Combo Therapy